{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:21:16Z","timestamp":1768015276671,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.heliyon.2019.e01304","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T06:09:02Z","timestamp":1551938942000},"page":"e01304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["QSAR study of anti-Human African Trypanosomiasis activity for 2-phenylimidazopyridines derivatives using DFT and Lipinski's descriptors"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-5101","authenticated-orcid":false,"given":"Samir","family":"Chtita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounir","family":"Ghamali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdellah","family":"Ousaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnane","family":"Aouidate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assia","family":"Belhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelali Idrissi","family":"Taourati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Hariram","family":"Masand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-8297","authenticated-orcid":false,"given":"Mohammed","family":"Bouachrine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahar","family":"Lakhlifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2019.e01304_bib1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/S0140-6736(09)60233-6","article-title":"Rescuing the bottom billion through control of neglected tropical diseases","volume":"373","author":"Hotez","year":"2009","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.heliyon.2019.e01304_bib2","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1016\/j.bmc.2015.04.077","article-title":"New developments in antiinfectives research for tropical infectious diseases","volume":"23","author":"Chibale","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.heliyon.2019.e01304_bib3","doi-asserted-by":"crossref","first-page":"11138","DOI":"10.1021\/cr500098f","article-title":"Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis","volume":"114","author":"Njoroge","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.heliyon.2019.e01304_bib4","unstructured":"www.who.int\/mediacentre\/factsheets\/fs259\/en\/. (Accessed 27 February 2019)."},{"key":"10.1016\/j.heliyon.2019.e01304_bib5","first-page":"1","article-title":"The history of African trypanosomiasis","volume":"3\u20133","author":"Steverding","year":"2008","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.heliyon.2019.e01304_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2019.e01304_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2217\/fmb.11.44","article-title":"Development of novel drugs for human African trypanosomiasis","volume":"6","author":"Brun","year":"2011","journal-title":"Future Microbiol."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01304_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.heliyon.2019.e01304_bib9","series-title":"Mapping the Risk of Human African Trypanosomiasis","author":"World Health organization WHO","year":"2016"},{"key":"10.1016\/j.heliyon.2019.e01304_bib10","series-title":"Human African (Sleeping Sickness)","author":"Trypanosomiasis","year":"2016"},{"key":"10.1016\/j.heliyon.2019.e01304_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2009.02.007","article-title":"Human African trypanosomiasis, chemotherapy and CNS disease","volume":"211","author":"Rodgers","year":"2009","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01304_bib12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/jm4017015","article-title":"Synthesis and biological evaluation of N,N\u2032-squaramides with high in\u00a0vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease","volume":"57","author":"Olmo","year":"2014","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.heliyon.2019.e01304_bib13","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1021\/jm701306r","article-title":"Complexation of the anti-trypanosoma cruzi drug benznidazole improves solubility and efficacy","volume":"51","author":"Nogueira Silva","year":"2008","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2019.e01304_bib14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/AAC.49.4.1521-1528.2005","article-title":"Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations","volume":"49","author":"Garcia","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"21","key":"10.1016\/j.heliyon.2019.e01304_bib15","doi-asserted-by":"crossref","first-page":"9686","DOI":"10.1021\/acs.jmedchem.6b00442","article-title":"Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides","volume":"59","author":"Russell","year":"2016","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.heliyon.2019.e01304_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pt.2003.09.001","article-title":"Specific chemotherapy of Chagas disease: controversies and advances","volume":"19","author":"Urbina","year":"2003","journal-title":"Trends Parasitol."},{"issue":"8","key":"10.1016\/j.heliyon.2019.e01304_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1191\/0960327106het653oa","article-title":"Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis)","volume":"25","author":"Castro","year":"2006","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.heliyon.2019.e01304_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1021\/jm401178t","article-title":"Substituted 2-henylimidazopyridines: a new class of drug leads for human African trypanosomiasis","volume":"57","author":"Tatipaka","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01304_bib19","first-page":"90","article-title":"Quantitative structure\u2013activity relationship studies of anticancer activity for Isatin (1H-indole-2,3-dione) derivatives based on density functional theory with electronic and topological descriptors","volume":"2","author":"Chtita","year":"2017","journal-title":"Int. J. Quant. Struct. Prop. Relatsh."},{"key":"10.1016\/j.heliyon.2019.e01304_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/5137289","article-title":"Investigation of antileishmanial activities of acridines derivatives against promastigotes and amastigotes form of parasites using quantitative structure activity relationship analysis","author":"Chtita","year":"2016","journal-title":"Adv. Phys. Chem."},{"key":"10.1016\/j.heliyon.2019.e01304_bib21","series-title":"Parac & Grimme Gaussian 03 2003","author":"Adamo","year":"2000"},{"key":"10.1016\/j.heliyon.2019.e01304_bib22","series-title":"PerkinElmer Informatics","author":"ChemBioOffice","year":"2010"},{"key":"10.1016\/j.heliyon.2019.e01304_bib23","series-title":"Software, XLSTAT Company","author":"XLSTAT","year":"2013"},{"issue":"3-4","key":"10.1016\/j.heliyon.2019.e01304_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/10629360902949567","article-title":"How not to develop a QSAR\/QSPR","volume":"20","author":"Dearden","year":"2009","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.heliyon.2019.e01304_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1108\/S1474-7979(2009)0000020014","article-title":"The use of partial least squares path modeling in international marketing","volume":"20","author":"Henseler","year":"2009","journal-title":"Adv. Int. Market."},{"key":"10.1016\/j.heliyon.2019.e01304_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lrp.2013.01.001","article-title":"Partial least squares structural equation modeling: rigorous applications, better results and higher acceptance","volume":"46","author":"Hair","year":"2013","journal-title":"Long. Range Plan."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01304_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2753\/MTP1069-6679190202","article-title":"PLS-SEM: indeed a silver bullet","volume":"19","author":"Hair","year":"2011","journal-title":"J. Mark. Theory Pract."},{"key":"10.1016\/j.heliyon.2019.e01304_bib28","series-title":"Business Research Methods","author":"Zikmund","year":"2000"},{"key":"10.1016\/j.heliyon.2019.e01304_bib29","series-title":"The Basic Practice of Statistics","author":"Moore","year":"2013"},{"key":"10.1016\/j.heliyon.2019.e01304_bib30","series-title":"Theory of Point Estimation","author":"Lehmann","year":"1998"},{"key":"10.1016\/j.heliyon.2019.e01304_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","article-title":"A caution regarding rules of thumb for variance inflation factors","volume":"41","author":"O\u2019Brien","year":"2007","journal-title":"Qual. Quantity"},{"issue":"12","key":"10.1016\/j.heliyon.2019.e01304_bib32","doi-asserted-by":"crossref","DOI":"10.1517\/17460441.2.12.1567","article-title":"On some aspects of validation of predictive quantitative structure\u2013activity relationship models","volume":"2","author":"Roy","year":"2007","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.heliyon.2019.e01304_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/cem.1180020106","article-title":"Selection of optimal regression models via cross validation","volume":"2","author":"Osten","year":"1998","journal-title":"J. Chemom."},{"key":"10.1016\/j.heliyon.2019.e01304_bib34","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0090-9556(24)15175-6","article-title":"Three and four-dimensional-quantitative structure activity relationship (3D\/4D-QSAR) analyses of CYP2C9 inhibitors","volume":"28","author":"Ekins","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.heliyon.2019.e01304_bib35","series-title":"OECD Guidance Document on the Validation of QSAR Models","year":"2007"},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01304_bib36","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1289\/ehp.5758","article-title":"Methods for reliability & uncertainty assessment & for applicability evaluations of classification & regression-based QSARs","volume":"111","author":"Eriksson","year":"2003","journal-title":"Environ. Health Persp."},{"issue":"5","key":"10.1016\/j.heliyon.2019.e01304_bib37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/qsar.200610151","article-title":"Principles of QSAR models validation: internal & external","volume":"26","author":"Gramatica","year":"2007","journal-title":"QSAR Comb. Sci."},{"key":"10.1016\/j.heliyon.2019.e01304_bib38","series-title":"How K-Nearest Neighbor Parameters Affect its Performance, Argentine Symposium on Artificial Intelligence","first-page":"1","author":"Batista","year":"2009"},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01304_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/026119290503300209","article-title":"Current status of methods for defining the applicability domain of (quantitative) structure\u2013activity relationships","volume":"33","author":"Netzeva","year":"2005","journal-title":"Altern. Lab. Anim."},{"issue":"1","key":"10.1016\/j.heliyon.2019.e01304_bib40","article-title":"The history & development of QSARs","volume":"1","author":"Dearden","year":"2016","journal-title":"Int. J. Quantit. Struct. Prop. Relatsh."},{"issue":"5","key":"10.1016\/j.heliyon.2019.e01304_bib41","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/ci060132x","article-title":"A novel Automated lazy learning QSAR (ALL-QSAR) Approach:\u2009 method development, Applications, and virtual screening of chemical databases using validated ALL-QSAR models","volume":"46","author":"Zhang","year":"2006","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.heliyon.2019.e01304_bib42","series-title":"A Primer on QSAR\/QSPR Modeling: Fundamental Concepts, Theoretical and Computational Chemistry","author":"Roy","year":"2015"},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01304_bib43","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/qsar.200510203","article-title":"A quantum-mechanical QSAR model to predict the refractive index of polymer matrices","volume":"25","author":"Holder","year":"2006","journal-title":"QSAR Comb. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01304_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jscs.2010.09.001","article-title":"QSAR based modeling on a series of \u03b1-hydroxy amides as a novel class of bradykinin B1 selective antagonists","volume":"15","author":"Srivastava","year":"2011","journal-title":"Journal of Saudi Chemical Society"},{"issue":"1\u20133","key":"10.1016\/j.heliyon.2019.e01304_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"6","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2019.e01304_bib46","series-title":"Chapter 13 - Solvents, Buffers, and Additives Used in the Mobile Phase, Selection of the HPLC Method in Chemical Analysis","first-page":"393","author":"Moldoveanu","year":"2017"},{"key":"10.1016\/j.heliyon.2019.e01304_bib47","series-title":"Chapter 5 - Determining Physical and Spectroscopic Properties, Experimental Organic Chemistry","first-page":"145","author":"Isac-Garc\u00eda","year":"2016"},{"key":"10.1016\/j.heliyon.2019.e01304_bib48","first-page":"43","article-title":"Quantitative structure\u2013activity relationship \u2013 a historical perspective and the future","volume":"4","author":"Hansch","year":"2007"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01304_bib49","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/ci0342932","article-title":"Theoretical scales of hydrogen bond Acidity and basicity for Application in QSAR\/QSPR studies and drug design","volume":"44","author":"Oliferenko","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.heliyon.2019.e01304_bib50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1126\/science.218.4574.747","article-title":"Role of frontier orbitals in chemical reactions","volume":"218","author":"Fukui","year":"1982","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01304_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jtusci.2014.10.006","article-title":"Quantitative structure\u2013activity relationship studies of dibenzo[a,d]cycloalkenimine derivatives for non-competitive antagonists of N-methyl-d-aspartate based on density functional theory with electronic and topological descriptors","volume":"9","author":"Chtita","year":"2015","journal-title":"J. Taibah Univ. Sci."},{"key":"10.1016\/j.heliyon.2019.e01304_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.molstruc.2016.11.012","article-title":"QSAR modeling for anti-human African trypanosomiasis activity of substituted 2-Phenylimidazopyridines","volume":"1130","author":"Masand","year":"2017","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.heliyon.2019.e01304_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.chemolab.2016.01.008","article-title":"Be aware of error measures. Further studies on validation of predictive QSAR models","volume":"152","author":"Roy","year":"2016","journal-title":"Chemometr. Intell. Lab. Syst."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844018388236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844018388236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:26:20Z","timestamp":1762511180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844018388236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2405844018388236"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e01304","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QSAR study of anti-Human African Trypanosomiasis activity for 2-phenylimidazopyridines derivatives using DFT and Lipinski's descriptors","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e01304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01304"}}